Product Description: OR-1855, an active metabolite of Levosimendan, has effect on human myometrial contractility. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure[1][2].
Applications: COVID-19-immunoregulation
Formula: C11H13N3O
References: [1]Banfor PN, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H238-48./[2]Mark P. Hehir, et al. 487: OR-1855, a levosimendan metabolite with an effect on human myometrial contractility.December 2009Volume 201, Issue 6, Supplement, Pages S182-S183.
CAS Number: 101328-85-2
Molecular Weight: 203.245
Compound Purity: 99.69
Research Area: Cardiovascular Disease
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Autophagy;Drug Metabolite;Phosphodiesterase (PDE);Potassium Channel
English
Deutsch
